JG
ACHN

Joel Greenblatt’s Achillion Pharmaceuticals ACHN Stock Holding History

Joel Greenblatt’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-191,792
Closed -$1.5M – 1099
2016
Q2 		$1.5M Sell
191,792
-362,333
-65% -$3.11M 0.02% 573
2016
Q1 		$4.28M Buy
+554,125
New +$4.06M 0.05% 458

Other funds holding ACHN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Joel Greenblatt's ACHN Position: Q3 2016 in Review

Joel Greenblatt sold out of Achillion Pharmaceuticals (ACHN) in Q3 2016, closing a stake of 191,792 shares — an estimated $1.5M sold.

Joel Greenblatt first reported a position in ACHN in Q1 2016 and held it in 2 quarters. The position peaked at $4.28M in Q1 2016. 162 funds tracked by Wall St. Rank hold ACHN as of Q3 2016.

  • Joel Greenblatt reported no remaining Achillion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Joel Greenblatt sold 191,792 Achillion Pharmaceuticals shares in Q3 2016, an estimated $1.5M.
  • Joel Greenblatt first reported a position in Achillion Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Joel Greenblatt's Achillion Pharmaceuticals position peaked at $4.28M in Q1 2016.
  • 162 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2016.

Based on Gotham Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.